Effect of D-003 on intravascular platelet aggregation induced with collagen in rats

Journal of Medicinal Food

Volumn 8, Issue 2, 2005, Pages 232-236

  Molina, Vivian ^a   Carbajal, Daisy ^a   Arruzazabala, Lourdes ^a   Más, Rosa ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Collagen; D 003; In vivo; Platelet aggregation; Sugar cane wax

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; D 003; WAX;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG PURIFICATION; GUINEA PIG; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUGARCANE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBUS;

ADMINISTRATION, ORAL; ANIMALS; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SACCHARUM; THROMBOSIS;

CAVIA; SACCHARUM; SACCHARUM OFFICINARUM; THROMBUS;

EID: 22444435682     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2005.8.232     Document Type: Article

References (28)

1. Puri RN, Colman RW: ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997;32:437-502.
2. Prencipe M, Culasso F, Rasura M, Anzini A, Beccia M, Cao M, Giubilei F, Fieschi C: Long-term prognosis after a minor stroke: 10-year mortality and major stroke recurrence rates in a hospital-based cohort. Stroke 1998;29:126-132.
3. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Antiplatelet agents and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-425.
4. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
5. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G: Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001;119(1 Suppl): 39S-63S.
6. Harbison JW: Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease. Am J Health Syst Pharm 1998; 55(Suppl):S17-S20.
7. Schafer A: Antiplatelet therapy. Am J Med 1996;101:199-209.
8. Cairns JA, Lewis HD Jr, Meade TW, Sutton GC, Theroux P: Antithrombotic agents in coronary artery disease. Chest 1995; 108(Suppl 4):380S-400S.
9. Sherman D, Dyken ML Jr, Gent M, Harrison JG, Hart RG, Mohr JP: Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995;108(Suppl 4):444S-456S.
10. Landmark K: Acetylsalicylic acid in the treatment of cardiovascular and cerebrovascular diseases. Tidsskr Nor Laegeforen 1997: 117:4432-4436.
11. Hassan M, Amonkar M: Aspirin for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res 2001;62: 676-690.
12. Awiry EH, Loscalzo J: Aspirin. Circulation 2000;101:1206-1208.
13. Lanas AI, Arroyo MT, Esteva F, Cornudella R, Hirschowitz BI, Sainz R: Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 1996;39:654-660.
14. McTavish D, Faulds D, Goa KL: Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990;40:238-259.
15. Coukell AJ, Markham A: Clopidogrel. Drugs 1997;54:745-750.
16. The CAPRIE Study Group: A randomized, blinded, trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
17. Creager MA: Results of the CAPRIE trial: Efficacy and safety of clopidogrel. Clopidrogel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998;3:257-260.
18. Gonzalez L, Marrero D. Laguna A, Mas R, Arruzazabala ML, Carbajal D, Cora M, Menéndez R (Laboratorios Dalmer SA): Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. PAT CU 35/97. December 30, 1997.
19. Molina V, Arruzazabala ML, Carbajal D, Mas R, Valdes S: Antiplatelet and antithrombotic effects of D-003. Pharmacol Res 2000;42:137-143.
20. Arruzazabala ML, Carbajal D, Mas R, Molina V, Castaño G, Gámez R: Effects of D-003. a new compound purified from sugarcane wax, on platelet aggregation in healthy volunteers. Clin Drug Invest 2003;23:107-118.
21. Arruzazabala ML, Carbajal D, Mas R, Garcia M, Fraga V: Effects of policosanol on platelet aggregation in rats. Thromb Res 1993; 69:321-327.
22. Cowan DH: Platelet adherence to collagen: Role of prostaglandin- thromboxane synthesis. Br J Haematol 1981;49:425-434.
23. Cowan DH, Robertson AL, Shook P, Giroski P: Platelet adherence to collagen: Role of plasme, ADP and divalent cations. Br J Haematol 1981;47:257-267.
24. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994-2998.
25. Bunting S, Gryglewski RJ, Moncada S, Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance which relaxes strips of mesenteric and celiac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913.
26. Moncada S, Herman AG, Higgs EA, Vane JR: Differential formation of prostacyclin (PgX or PgI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977;11:323-344.
27. Molina V, Arruzazabala ML, Carbajal D, Mas R: D-003, a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites. Prostaglandins Leukot Essent Fatty Acids 2002;67:19-24.
28. Molina V, Arruzazabala ML, Carbajal D, Mas R: Synergistic effect of D-003 and aspirin on experimental thrombosis models. Prostaglandins Leukot Essent Fatty Acids 2003;68:305-310.